The classic scenario is in mature B-cell lymphomas, such as Burkitt lymphoma, in which the IGH enhancer activates MYC, or follicular lymphoma, in which the IGH enhancer activates BCL2. This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.